William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating on October 27.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Phipps has given his Buy rating due to a combination of factors including Genmab’s strong financial performance and promising pipeline developments. The company reported third-quarter revenues that exceeded expectations, driven by higher royalties and product sales, which indicates robust financial health and steady revenue growth.
Furthermore, despite a slight miss in Epkinly sales, the overall guidance remains intact, and the company is on track with its late-stage pipeline developments. With several significant catalysts anticipated towards the end of 2025 and into 2026, including potential FDA approvals and pivotal trial readouts, Genmab’s pipeline holds the potential for long-term revenue growth, reinforcing the Buy rating.
Phipps covers the Healthcare sector, focusing on stocks such as Merus, Upstream Bio, Inc., and Bristol-Myers Squibb. According to TipRanks, Phipps has an average return of 2.0% and a 44.98% success rate on recommended stocks.